PreciPoint Group GmbH has successfully closed its Series A financing round of EUR 10 million. Existing investors, including bm‑t beteiligungsmanagement thüringen gmbh (bm|t), and a new family office invested in the German MedTech startup. This financing round will advance the international commercialization of the company´s first IVD medical product, market entry in the USA as well as further technological development of additional innovative solutions.
In 2022, PreciPoint will commercially launch the iO:M8 ROSE, a globally unique solution for the digitization of intraoperative microscopic assessments during cancer surgeries. These examinations, during which pathologists determine whether sufficient material has been removed from the patient’s body and whether the margins are free of cancer cells, are traditionally performed by specialists being bound to location and time using classic light microscopes for imaging. PreciPoint’s solutions enable entirely new ways of working, allowing significant cost savings and, most importantly, better patient care.
PreciPoint specializes in the digitization of microscopy and laboratory workflows. The company offers solutions for applications in medicine, research, and education and its devices are used in many laboratories worldwide. It is central to PreciPoint’s philosophy to develop products together with users. Thus, the company works with many respected pathologists in Germany to design products that meet the highest standards while being quick and easy to use. This includes a focus on the development of technologies for Label-Free Diagnostics, where samples can be viewed entirely without expensive and time-consuming sample preparation, as well as the development of product solutions for high-speed applications to help meet the increasing demand in pathology labs.
Excellent prospects that also convinced the investors: “Since our seed investment in 2019, the team around the two co-founders and managing directors Nicolas Weiss and Dominik Gerber has made enormous progress. Renowned distribution partners could be acquired, new products could be developed and successfully placed on the market. At the same time, the prerequisites were created to quickly scale the company. We firmly believe that PreciPoint, as a ISO13485 certified medical device company, will be able to successfully position its product portfolio on the European and American markets,” said Stefan Jahn, Senior Investment Manager at bm|t.
PreciPoint specializes in the development, production, and marketing of innovative digitization solutions and photonics systems in the field of microscopy. Already offered on the market are the microscopy solutions M8, O8 as well as FRITZ. All devices are fully motorized transmitted light microscopes users control via software. The solutions work digitally, do not require an eyepiece, and produce high-resolution images of the samples, which can easily be stored digitally. The microscopes impress with easy and intuitive user interfaces. Furthermore, the devices can be equipped with a remote function so that they can also be accessed from any location. In addition to hardware products, the company offers versatile software applications with which the images can be visualized, processed, and analyzed. The virtual microscopy platform PreciCloud enables new working models between experts, researchers, and students. PreciPoint’s customer base already includes many well-known users worldwide. Based in Freising, Germany, PreciPoint is an ISO 13485 certified medical device company and one of the Top Startups in Germany. The company has won various awards, including 3rd place as Top Innovator 2022, in which PreciPoint prevailed as a particularly innovative company against almost 450 companies, and the award as Top Startup Employer in the healthcare sector.
About bm‑t beteiligungsmanagement thüringen gmbh (bm|t)
Erfurt-based, bm|t is the first address for investments in Thuringia, Germany. bm|t currently manages nine funds with a total volume of over EUR 350 million and invests in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.